Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A3 | Q01959 | 19/20 | 0.67 |
| ▸ | SLC6A4 | P31645 | 17/20 | 0.67 |
| ▸ | SLC6A2 | P23975 | 7/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4656331 | 0.82 | SLC6A3 (0.64) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL8241080 | 0.80 | SLC6A3 (1.00) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4657320 | 0.80 | SLC6A4 (0.48) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL5166600 | 0.79 | SLC6A4 (0.64) | SLC6A3SLC6A4SLC6A2 | |
| Hydrochloric Acid SCHEMBL3520749 | 0.79 | SLC6A3 (0.97) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL4656897 | 0.78 | SLC6A4 (0.69) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL12585891 | 0.78 | SLC6A3 (0.71) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL17888282 | 0.77 | OPRM1 (0.50) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL3155718 | 0.76 | OPRM1 (0.51) | SLC6A3SLC6A4SLC6A2 | |
| SCHEMBL16838117 | 0.76 | SLC6A3 (0.46) | SLC6A3SLC6A4SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1549615-B1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2008-12-03 | — | — | EP | disclosed |
| US-20060241142-A1 | Naphthamide derivatives and their use | ALEATEL WIRELESS, INC. | 2006-10-26 | — | — | US | disclosed |
| EP-1549615-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | AstraZeneca AB (SE) | 2005-07-06 | — | — | EP | disclosed |
| WO-2004020411-A1 | NAPHTHAMIDE DERIVATIVES AND THEIR USE | ASTRAZENECA AB (SE) | 2004-03-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241142-A1 | Naphthamide derivatives and their use | NPM1, H1-4, H1-3 | SLC6A3 2056/4885SLC6A4 1749/4885SLC6A2 900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.